Summary: In adults with overweight or obesity following 7-day vancomycin treatment, 2′-fucosyllactose (2′-FL) supplementation for 8 weeks transiently improved gut…
Browsing: All
Summary: In patients with type 2 diabetes inadequately controlled on metformin (n=60), adding sitagliptin 100 mg/day to metformin 2000 mg/day…
Summary: In patients with type 2 diabetes inadequately controlled on metformin and glyburide (n=32), sitagliptin add-on therapy for 6 months…
Summary: In adults with type 2 diabetes (n=40), Dibifree dietary phytomix (15 g/day) as add-on therapy significantly reduced HbA1c, fasting/postprandial…
In patients with type 2 diabetes (T2D), once-weekly semaglutide significantly increased the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to non-exposure, doubling the five-year hazard ratio (HR), though it was associated with improved glycaemic control and other cardiometabolic benefits.
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
A clinical guideline update on the prevention or delay of diabetes and associated comorbidities was published in January 2025 by the American Diabetes Association (ADA) Professional Practice Committee. These guidelines, published in Diabetes Care (2025;48(Suppl. 1):S50–S58).
Summary: In 178 adults with T2D (HbA1c 7.0-10.5%) on stable metformin, once-weekly semaglutide (0.25-1.0 mg) for 52 weeks produced numerically…
Summary: In 1,748 adults with T2D (HbA1c 7.5-10.0%) inadequately controlled on basal insulin glargine and metformin, once-weekly semaglutide 1.0 mg…
Summary: In 788 adults with T2D (HbA1c 7.0-10.5%) inadequately controlled on stable metformin, BMI ≥25, once-weekly semaglutide 1.0 mg for…